RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,536,122 | +1827.7% | 854,395 | +1580.8% | 0.03% | +1500.0% |
| Q1 2023 | $339,063 | -24.7% | 50,834 | -8.0% | 0.00% | 0.0% |
| Q2 2022 | $450,000 | -80.8% | 55,266 | -83.1% | 0.00% | -84.6% |
| Q1 2022 | $2,346,000 | -63.7% | 327,635 | -13.3% | 0.01% | -62.9% |
| Q4 2021 | $6,470,000 | – | 377,717 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $77,730,340 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $44,380,166 | 32.86% |
| MV Management XI, L.L.C. | 1,971,908 | $14,730,153 | 25.77% |
| MIC Capital Management UK LLP | 8,451,758 | $63,134,635 | 12.84% |
| Yong Rong (HK) Asset Management Ltd | 1,174,200 | $8,772 | 3.85% |
| ArchPoint Investors | 1,114,626 | $8,326,256 | 3.22% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,711,148 | $20,252,276 | 0.70% |
| HARVARD MANAGEMENT CO INC | 882,129 | $6,590 | 0.65% |
| Diametric Capital, LP | 119,906 | $895,698 | 0.40% |
| Lingotto Investment Management LLP | 775,077 | $5,789,825 | 0.37% |